Latest Coronary Stent Technology Available at Stormont-Vail Regional Health Center for Treatment of Coronary Artery Disease(Topeka, Kan., July 7, 2008) – Stormont-Vail HealthCare announced today that Jack Jones, M.D., interventional cardiologist and medical director of the Stormont-Vail Catheterization Lab, successfully implanted the newest FDA approved drug eluting stent available for the treatment of patients with coronary artery disease. This new device called the XIENCE™ V Everolimus Eluting Coronary Stent System received FDA approval on Wednesday, July 2, 2008. This makes Stormont-Vail one of the first facilities in nation to begin using the XIENCE™ V Everolimus Eluting Coronary Stent and to enroll a patient into the XIENCE V USA study. “Stormont-Vail Regional Health Center, working in tandem with the Cotton-O’Neil Heart Center, prides itself on being able to remain on the cutting edge of patient care. The availability of XIENCE V signifies an advancement in the treatment options we are able to offer our patients," said Jack Jones, M.D., cardiologist and medical director of the Stormont-Vail Cardiovascular Catheterization Lab. "Compared to the most widely used drug eluting stent, XIENCE V has been shown to reduce cardiac events such as heart attacks, death and the need for a repeat procedure." Coronary artery disease is a serious condition that occurs when plaque buildup narrows or blocks the arteries and reduces blood flow to the heart. The blockage can lead to chest pain, shortness of breath or even a heart attack. In the United States, coronary artery disease is the most common type of heart disease and is the leading cause of death for both men and women.
XIENCE V is built upon the world’s most popular bare metal stent system, MULTI-LINK VISION®. The system design offers physicians the ability to deliver the stent to the precise location of the blockage with ease, quickly restoring blood flow to the heart. The U.S. Food and Drug Administration approved the XIENCE V stent, manufactured by Abbott, July 2, 2008. In two clinical trials, XIENCE V has been shown to be superior to the most widely used drug eluting stent, the TAXUS® Paclitaxel-Eluting Coronary Stent System. In the SPIRIT II trial, XIENCE V demonstrated superiority compared to TAXUS with a statistically significant 69 percent reduction in the primary endpoint of in-stent late loss at six months (mean, 0.11mm for XIENCE V vs. 0.36 mm for TAXUS, PNI and PSUP <0.0001). In the SPIRIT III trial, XIENCE V demonstrated superiority compared to TAXUS with a statistically significant 50 percent reduction in the primary endpoint of in-segment late-loss at 8 months (mean, 0.14 mm for XIENCE V vs. 0.28mm for TAXUS, PNI < 0.0001, PSUP =0.004). In addition, XIENCE V demonstrated a 45 percent reduced risk of major adverse cardiac events such as heart attack, death and the need for repeat procedure compared to TAXUS at two years in the SPIRIT III trial. For more information about XIENCE V, please visit www.xiencev.com. For more information about Stormont-Vail Regional Health Center, please visit www.stormontvail.org.
|
A stent, or tiny wire mesh tube, is inserted into a clogged artery during a minimally invasive angioplasty procedure. The stent props open the artery and restores blood flow to the heart. Drug eluting stents are coated with a medication (everolimus, in the case of XIENCE V) which is released in a controlled fashion over time to prevent the artery from renarrowing, thereby decreasing the need for a follow-up procedure.